Outcomes include:
(1) the count and proportion of patients with evidence of having performed CBC, lipid panel, TB screening, and viral hepatitis B and C screening tests within 3 months prior to initiation of abrocitinib;
(2) the count and proportion of patients with evidence of having performed the CBC and lipid panel laboratory tests at week 4 (± 2 weeks) after initiation of abrocitinib;
(3) the proportion of patients with evidence of having risk factors and the number of risk factors for VTE, MACE, malignancy excluding NMSC, NMSC, and serious infection (including age 65 years or older, estimated dose of >100 mg/day for patients ages 65 or older, history of atherosclerotic disease, malignancy, pregnancy, history of VTE, use of combined hormonal contraceptives or hormone replacement therapy, major surgery, inherited coagulation disorder, diabetes, history of serious or opportunistic infection, TB) within 6 months prior to initiation of treatment with abrocitinib;
(4) the count and proportion of patients with evidence of having received live attenuated vaccines (e.g., measles, mumps, rubella) 4 weeks prior to and during treatment with abrocitinib;
(5) the count and proportion (among all pregnant women identifiable in a given database) of women in whom pregnancy overlaps with abrocitinib use;
(6) the count and proportion patients identified with severe hepatic impairment up to 6 months prior to or during treatment with abrocitinib;
(7) the count and proportion of patients aged <12 years on the index date; and (8) the count of proportion of patients with an estimated starting dose > 100mg/day, and a description of the duration of use (median and IQR).